PAR PHARM INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?
PAR PHARM INC has twelve approved drugs.
There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.
There are nine patent family members on PAR PHARM INC drugs in eight countries and twenty-three supplementary protection certificates in thirteen countries.
Summary for PAR PHARM INC
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 12 |
Drugs and US Patents for PAR PHARM INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm Inc | DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 206159-006 | May 31, 2019 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm Inc | ALOSETRON HYDROCHLORIDE | alosetron hydrochloride | TABLET;ORAL | 206113-001 | Feb 23, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Par Pharm Inc | PHENOXYBENZAMINE HYDROCHLORIDE | phenoxybenzamine hydrochloride | CAPSULE;ORAL | 204522-001 | Jan 24, 2017 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Par Pharm Inc | ANTIZOL | fomepizole | INJECTABLE;INJECTION | 020696-001 | Dec 4, 1997 | DISCN | Yes | No | 7,553,863 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PAR PHARM INC Drugs
Supplementary Protection Certificates for PAR PHARM INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2101777 | 300813 | Netherlands | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125 |
| 2330892 | 63/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REGISTRATION NO/DATE: EU/1/15/1062 (MITTEILUNG) 20151201 |
| 2101777 | PA2016018 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AMBRISENTANAS; REGISTRATION NO/DATE: EU/1/08/451 (001-004) 20151120 |
| 2101777 | 122016000039 | Germany | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
